Journals / Turkish Journal of Urology / 2021 / Cilt: 47 - Sayı: 5

Current advances in neuromodulation techniques in urology practices: A review of literature

Pages
375–385
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We included reviews, meta-analyses, randomized controlled trials, and prospective and retrospective studies to evaluate the activities and reliability of SNM, PN, and PTNS and the developments in this area in the last decade based on the current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuromodulation has become a valid therapeutic option for patients with various lower urinary tract disorders.
📊
Key Findings & Data:We performed a literature search using Medline (PubMed), Cochrane Library, EMBASE, and Google scholar databases in the English language from January 2010 to February 2021.
💡
Conclusion & Impact:We included reviews, meta-analyses, randomized controlled trials, and prospective and retrospective studies to evaluate the activities and reliability of SNM, PN, and PTNS and the developments in this area in the last decade based on the current literature.
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Özet

Neuromodulation has become a valid therapeutic option for patients with various lower urinary tract disorders. In clinical practice, the most used and recommended neuromodulation techniques are sacral neuromodulation (SNM), pudendal neuromodulation (PN), and percutaneous tibial nerve stimulation (PTNS). There are many theories concerning the mechanism of action of neuromodulation. Although SNM, PN, and PTNS show their activities through different nerve roots, all provide central and peripheral nervous system modulations. SNM has been approved for the treatment of overactive bladder (OAB), nonobstructive urinary retention, and fecal incontinence, while PTNS has been approved for OAB treatment. However, they are also used off-label in other urinary and nonurinary pelvic floor disorders, such as neurogenic lower urinary system disorder, interstitial cystitis, chronic pelvic pain, and sexual dysfunction. Minor and nonsurgical reversible complications are usually seen after neuromodulation techniques. In addition, in the last few years, there have been various developments in neuromodulation technology. Some of the examples of these developments are rechargeable batteries with wireless charging, improvements in programing, less invasive single-stage implantation in outpatient settings, and lower-cost new devices. We performed a literature search using Medline (PubMed), Cochrane Library, EMBASE, and Google scholar databases in the English language from January 2010 to February 2021. We included reviews, meta-analyses, randomized controlled trials, and prospective and retrospective studies to evaluate the activities and reliability of SNM, PN, and PTNS and the developments in this area in the last decade based on the current literature.

🔖

Cite This Article

EROL, B., DANACIOĞLU, Y. O., PETERS, K. M. (2021). Current advances in neuromodulation techniques in urology practices: A review of literature. Turkish Journal of Urology, Cilt: 47 - Sayı: 5, 375–385. https://ajindex.com/articles/402997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Yih JM, Killinger KA, Boura JA, Peters KM. Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med. 2013
  2. 10(10):2477-2483. [CrossRef] 2. Roy H, Offiah I, Dua A. Neuromodulation for pelvic and urogenital pain. Brain Sci. 2018
  3. 8(10):180. [CrossRef] 3. Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol. 2013
  4. 10(9):513-521. [CrossRef] 4. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: A clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012
  5. 13(5):327-334. [CrossRef] 5. Laviana A, Jellison F, Kim J-H. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome. Neurosurg Clin. 2014
  6. 25(1):33-46. [CrossRef] 6. Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients. Neurourol Urodynam. 2017
  7. 36(2):354-359. [CrossRef] 7. Krames ES, Peckham PH, Rezai A, Aboelsaad F. What is Neuromodulation? Neuromodulation. Amsterdam: Elsevier, 2009: 3-8. 8. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009
  8. :CD004202. 9. Goldman HB, Lloyd JC, Noblett KL, et al. International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn. 2018
  9. 37(5):1823-1848. [CrossRef] 10. Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in nonneurogenic lower urinary tract dysfunction and chronic pelvic pain: A systematic review of the literature. Eur Urol. 2018
  10. 73(3):406-418. [CrossRef] 11. El-Azab AS, Siegel SW. Sacral neuromodulation for female pelvic floor disorders. Arab J Urol. 2019
  11. 17(1):14-22. [CrossRef] 12. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/ SUFU guideline amendment 2019. J Urol. 2019
  12. 202(3):558-563. [CrossRef] 13. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015
  13. 193(5):1572- 1580. [CrossRef] 14. Groenendijk IM, Groen J, Scheepe JR, Blok BF. Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic param